| アブストラクト | BACKGROUND: Five-alpha reductase inhibitors (5alphaRIs) are used to treat benign prostatic hyperplasia (BPH). However, the cardiovascular effects of 5alphaRIs remain poorly understood. The study objective was to compare the rate of hospitalization for heart failure among men with BPH prescribed 5alphaRIs to that of men with BPH not prescribed BPH medications. METHODS: Using the Clinical Practice Research Datalink linked with hospitalization and vital statistics data, we conducted a population-based cohort study among patients newly diagnosed with BPH. We defined exposure as the current use of 5alphaRIs, current use of alpha-blockers, and no current use of BPH medications in a time-varying approach. The primary endpoint was hospitalization for heart failure, and secondary endpoints were myocardial infarction, stroke, and cardiovascular death. We used time-dependent Cox-proportional hazards models to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Our cohort included 94,440 men with incident BPH. A total of 3893 hospitalizations for heart failure occurred over 527,660 person-years of follow-up (incidence rate 7.38; 95% CI, 7.15-7.61, per 1000 person-years). Compared with no current use of BPH medications, current use of 5alphaRIs was not associated with an increased risk of hospitalization for heart failure (HR 0.94; 95% CI, 0.86-1.03), myocardial infarction (HR 0.92; 95% CI, 0.81-1.05), stroke (HR 0.94; 95% CI, 0.85-1.05), or cardiovascular death (HR 0.89; 95% CI, 0.80-0.99). CONCLUSIONS: The use of 5alphaRIs was not associated with an increased risk of hospitalization for heart failure, myocardial infarction, stroke, or cardiovascular death compared with non-use. |
|---|
| 組織名 | Department of Epidemiology, Biostatistics, Occupational Health, McGill;University, Montreal, Quebec, Canada; Center for Clinical Epidemiology, Lady;Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.;Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;Montreal, Quebec, Canada.;Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada; Gerald;Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.;Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada; Department of;Pediatrics, McGill University, Montreal, Quebec, Canada.;Department of Surgery, Urology Unit, Hopital Maisonneuve-Rosemont, Montreal,;Canada.;Medicine, McGill University, Montreal, Quebec, Canada. Electronic address:;kristian.filion@mcgill.ca. |
|---|
